Shots:
- Amgen, UCB, and Takeda reported that the first patient has been enrolled in the COMMUNITY trial. The study will test whether Amgen’s Otezla, Takeda’s lanadelumab, and UCB’s zilucoplan can reduce the severity of COVID-19 in hospitalized patients by moderating the immune system’s response to the disease
- The focus of the trial is to identify an effective treatment for hospitalized COVID-19 patients, who are Grade 2 to Grade 5 on a clinical severity status 8-point ordinal scale. Trial sites are being established in hospitals across the globe to support enrollment in communities
- This is the first time that the global pharmaceutical has come together to launch an adaptive clinical trial
Click here to read full press release/ article | Ref: Takeda | Image: Stat
The post Member of COVID R&D Alliance Report the First Patient Enrollment in COMMUNITY Study first appeared on PharmaShots.
